State governments use a system of open formularies known as preferred drug lists in Medicaid and other programs that purchase pharmaceuticals in order to control costs. The safety, efficacy, and cost effectiveness of new treatments are compared to existing ones, and the best drugs are included in the PDL. Federal trade policy seeks to limit this type of evidence-based pricing.
Trade, Policy and IP
PIJIP News
PIJIP to Meet With Coordinators of the Africa Group, Asia Pacific Group, and GRULAC Ahead of WIPO Secretary Briefing
16 Apr, 2024
Our department has invited the coordinators of the Africa Group, Asia Pacific Group, GRULAC, and their members to an off-the-record technical assistance workshop for delegations and capital officials.
Read morePIJIP Senior Research Analyst Andres Izquierdo named Co-Chair of the Sub-Committee on AI and Copyright at the American Intellectual Property Law Association
01 Apr, 2024
PIJIP Senior Research Analyst Andres Izquierdo was recently named Co-Chair of the Sub-Committee on Artificial Intelligence and Copyright at the American Intellectual Property Law Association (AIPLA).
Read moreProfessor Christine Haight Farley just published "The Stunted Development of Unfair Competition Law in the United States and Canada" in the Oxford Journal of IP Law & Practice
01 Apr, 2024
Professor Farley's new article compares trademark law in the U.S. and Canada to explore the limitations of federal and state or provincial law.
Read more